Swiss drugmaker Novartis AG's (NOVN.VX) race to get the first multiple sclerosis pill to market reaches a pivotal point next week when U.S. experts vote on whether Gilenia should be recommended for approval.
A green light is far from assured. Although the new drug has outperformed current injectable medicines in trials, it is associated with a range of potentially serious side effects that could limit its use or block it from the market altogether.
Industry analysts at Citigroup think the safety issues on Gilenia are a "50/50 call" and the market generally is cautious, suggesting scope for significant share price moves depending on the outcome of the June 10 advisory meeting.
via reuters.com
No comments:
Post a Comment